European CHMP recommends marketing authorization under exceptional circumstances for obiltoxaximab SFL for the treatment of inhalation anthrax

Obiltoxaximab is a monoclonal antibody that binds to the protective antigen (PA) of Bacillus anthracis toxin, thereby inhibiting binding of PA to its cellular receptors and preventing intracellular entry of the toxin components. A final decision is awaited.

Source:

Biospace Inc.